NervGen Pharma

Historical price data

NervGen Pharma is on a mission to transform the treatment of nervous system damage by developing first-in-class drugs that promote repair and functional recovery, moving beyond symptom management. Its core achievement is advancing NVG-291, a potentially best-in-class PTPσ inhibitor, into a Phase 1b/2a trial for spinal cord injury (SCI) with plans for expansion into Alzheimer's and MS. The strategy leverages a deep scientific foundation in neural inhibition mechanisms and is executed by a seasoned leadership team with proven CNS drug development and regulatory expertise. NervGen's approach addresses a vast, underserved market where no disease-modifying regenerative therapies currently exist.

Platform centered on inhibiting the Protein Tyrosine Phosphatase Sigma (PTPσ) receptor to release molecular brakes that prevent axonal regeneration and neural plasticity following nervous system injury or disease.

NervGen is a first-mover in direct PTPσ inhibition, facing limited direct competition. It competes broadly in neuroregeneration against cell therapy approaches (e.g., Lineage Cell) and other inhibitory pathway targets (e.g., Nogo, RGMa), where prior programs have struggled. In Alzheimer's, it would compete with anti-amyloid therapies but offers a distinct reparative mechanism.